Angiomax
Evidence Grade A — Regulatory approved. 1886 published studies. 92 registered clinical trials.
Loading...
Bivalirudin (sold as Angiomax) is a hospital blood thinner given through an IV drip during heart procedures such as coronary stenting. Originally inspired by the natural anticoagulant found in medicinal leeches, it is especially valuable for patients who cannot safely receive heparin. Its effects wear off predictably within about 25 minutes of stopping the infusion, giving doctors precise control.
1,886 published studies: 1607 human, 25 animal, 60 in-vitro, 501 reviews
Bivalirudin is marketed as Angiomax (approved December 2000), with generic versions available. It is indicated for coronary interventions, particularly in patients with or at risk of heparin-induced thrombocytopenia (HIT) — a dangerous allergic reaction to heparin where the immune system attacks platelets.
The HORIZONS-AMI trial in heart attack patients showed bivalirudin reduced major bleeding by 40% compared to heparin plus a GPIIb/IIIa inhibitor. However, it was associated with a higher rate of early stent clotting (acute stent thrombosis), which has tempered enthusiasm. Bivalirudin's role has narrowed as radial artery access (which reduces bleeding) has become standard, but it remains the go-to anticoagulant when heparin cannot be used.
Bivalirudin grabs thrombin — the key enzyme that converts fibrinogen into fibrin clots — at two separate points simultaneously, blocking both its active site and its fibrinogen-binding site. This dual grip provides powerful and specific anticoagulation. Crucially, thrombin slowly chews through the bivalirudin molecule itself, breaking free over about 25 minutes. This self-limiting mechanism means anticoagulation wears off predictably and quickly once the infusion stops — a significant safety advantage over heparin, which can be unpredictable and requires monitoring.
Bivalirudin's evidence comes from large cardiology trials involving thousands of patients. The HORIZONS-AMI trial showed a 40% reduction in major bleeding compared to heparin-based regimens in heart attack patients. However, it was also linked to a higher rate of early stent clotting, which tempered initial enthusiasm. The drug's clinical niche has narrowed over time. It was originally positioned as a safer alternative when used alongside powerful anti-platelet infusions, but as those infusions fell out of routine use, the bleeding advantage over heparin alone became less compelling. Today, bivalirudin is used primarily in patients with heparin-induced thrombocytopenia — a dangerous immune reaction to heparin — where a non-heparin anticoagulant is essential. No major new research programmes are active.
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 9
EMA Marketing Authorisation
FDA SUPPL 6
FDA SUPPL 14
FDA SUPPL 11
FDA SUPPL 23
FDA SUPPL 25
FDA SUPPL 27
FDA SUPPL 28
FDA SUPPL 29
FDA SUPPL 30
FDA SUPPL 31
FDA SUPPL 32
FDA SUPPL 35
FDA SUPPL 34
FDA SUPPL 36
FDA SUPPL 33
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 37
FDA SUPPL 39
FDA ORIG 1
FDA SUPPL 3
FDA SUPPL 1
FDA SUPPL 5
FDA SUPPL 1
FDA SUPPL 2
FDA ORIG 1
Health Canada Market Authorisation
FDA SUPPL 2
FDA ORIG 1
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 2
FDA SUPPL 7
FDA SUPPL 5
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
